Journey Medical Corp (DERM)vsZoetis Inc (ZTS)
DERM
Journey Medical Corp
$6.45
+4.88%
HEALTHCARE · Cap: $181.18M
ZTS
Zoetis Inc
$76.03
-2.44%
HEALTHCARE · Cap: $32.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 14636% more annual revenue ($9.53B vs $64.68M). ZTS leads profitability with a 28.0% profit margin vs -14.8%. ZTS earns a higher WallStSmart Score of 66/100 (B-).
DERM
Avoid28
out of 100
Grade: F
ZTS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.8%
Fair Value
$4.79
Current Price
$6.45
$1.66 premium
Margin of Safety
+10.8%
Fair Value
$144.23
Current Price
$76.03
$68.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.5% year-over-year
Every $100 of equity generates 82 in profit
Strong operational efficiency at 36.6%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -31.1% — below average capital efficiency
Expensive relative to growth rate
Trading at 9.7x book value
2.9% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : DERM
The strongest argument for DERM centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.0% and operating margin at 36.6%.
Bear Case : DERM
The primary concerns for DERM are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.86 is elevated, increasing financial risk.
Key Dynamics to Monitor
DERM profiles as a growth stock while ZTS is a value play — different risk/reward profiles.
DERM carries more volatility with a beta of 1.07 — expect wider price swings.
DERM is growing revenue faster at 21.5% — sustainability is the question.
ZTS generates stronger free cash flow (291M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (66/100 vs 28/100), backed by strong 28.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Journey Medical Corp
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Dermira, Inc., a biopharmaceutical company, develops and markets therapies for patients with dermatological diseases in the United States.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?